Supply Chain Intelligence

Disc Medicine, Inc. Supply Chain

IRON supply chain intelligence for Disc Medicine, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

IRON ·Last updated 2026-09-13 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

6Suppliers
13Customers
3Debt Items
20Related Chains

Source-Backed Evidence Depth

Disc Medicine, Inc. (IRON) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

23Total relationships
2Distinct source URLs
9High confidence
0.746Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Disc Medicine, Inc. Suppliers

TickerNameConfidenceEvidence
ABBV AbbVie Inc. 92% Under the AbbVie Agreement, we obtained an exclusive, worldwide license, with the right to sublicense to commercial pharmaceutical and biopharmaceutical companies under certain patents and technical …
ABBV AbbVie Inc. 92% Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON graph: Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON graph: Reciprocal relationship from ABBV g…
ABBVIE-DEUTSCHLAND-GMBH-CO-KG ABBVIE-DEUTSCHLAND-GMBH-CO-KG 92% Under the license agreement with AbbVie, or the AbbVie Agreement, we obtained an exclusive, worldwide license, with the right to sublicense to commercial pharmaceutical and biopharmaceutical companie…
ROCHE ROCHE 92% Pursuant to the terms of the Roche Agreement and in connection with the Company's reverse merger with Gemini, the Company issued 482,313 shares of the Company to Roche for no consideration.
MABWELL-THERAPEUTICS-INC MABWELL-THERAPEUTICS-INC 90% In January 2023, the Company entered into an exclusive license agreement with Mabwell pursuant to which Mabwell granted the Company an exclusive and sublicensable license to certain Mabwell intellect…
GLTO Damora Therapeutics, Inc. 72% Reciprocal relationship from GLTO graph: 026, we had an accumulated deficit of $515.1 million. We expect to continue to incur losses for the foreseeable future. Our operating expenses and net losses …

Disc Medicine, Inc. Customers

TickerNameConfidenceEvidence
HTGC Hercules Capital, Inc. 72% Reciprocal relationship from HTGC graph: Reciprocal relationship from IRON graph: Reciprocal relationship from HTGC graph: Reciprocal relationship from IRON graph: Reciprocal relationship from HTGC g…
HTGC Hercules Capital, Inc. 72% the agreement, the Company received an upfront payment of $ 0.2 million with additional consideration receivable upon the achievement of certain clinical, regulatory and sales milestones up to $ 7.0 …
ABBV AbbVie Inc. 62% Reciprocal relationship from ABBV graph: Reciprocal relationship from IRON graph: s, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, pu…
ABBVIE-DEUTSCHLAND-GMBH ABBVIE-DEUTSCHLAND-GMBH 62% s, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral…
CAPITAL-RESOURCES CAPITAL-RESOURCES 62% ed selling, general and administrative headcount, including an increase of $2.8 million in stock-based compensation driven by awards granted under our equity compensation plans and an increase of $1.…
CRS Carpenter Technology Corporation 62% Reciprocal relationship from CRS graph: Reciprocal relationship from IRON graph: Reciprocal relationship from CRS graph: Reciprocal relationship from IRON graph: Reciprocal relationship from CRS grap…
F-HOFFMANN-LA-ROCHE-LTD F-HOFFMANN-LA-ROCHE-LTD 62% expense ( 9,187 ) ( 1,668 ) Other external research and development expense ( 2,165 ) ( 1,832 ) Internal and other research and development expense ( 11,312 ) ( 6,748 ) Commercial expense $ ( 8,434 )…
GEMINI-THERAPEUTICS-INC GEMINI-THERAPEUTICS-INC 62% ering from hematologic diseases. The Company was founded in October 2017. The Company’s principal offices are located in Watertown, Massachusetts. The Company is subject to a number of risks and unce…
GEMSTONE-MERGER-SUB-INC GEMSTONE-MERGER-SUB-INC 62% ering from hematologic diseases. The Company was founded in October 2017. The Company’s principal offices are located in Watertown, Massachusetts. The Company is subject to a number of risks and unce…
HOFFMANN-LA-ROCHE-INC HOFFMANN-LA-ROCHE-INC 62% expense ( 9,187 ) ( 1,668 ) Other external research and development expense ( 2,165 ) ( 1,832 ) Internal and other research and development expense ( 11,312 ) ( 6,748 ) Commercial expense $ ( 8,434 )…
MABWELL-THERAPEUTICS-INC MABWELL-THERAPEUTICS-INC 62% expense ( 9,187 ) ( 1,668 ) Other external research and development expense ( 2,165 ) ( 1,832 ) Internal and other research and development expense ( 11,312 ) ( 6,748 ) Commercial expense $ ( 8,434 )…
SI Shoulder Innovations, Inc. 62% Reciprocal relationship from SI graph: Reciprocal relationship from IRON graph: , or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks generall…
SILVERGATE-CAPITAL-CORP SILVERGATE-CAPITAL-CORP 62% , or otherwise compromise our confidential or proprietary information and disrupt our operations. Cyberattacks generally are increasing in their frequency, sophistication and intensity, and have beco…

Disc Medicine, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
IRON-DEBT-10364 Warrants outstanding: 5.46 90% xbrl warrant detail from xbrl 2020-12-31.
IRON-DEBT Debt stack $59.3M 90% Market cache reports total debt of $59.3M.
IRON-DEBT-10365 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.

Disc Medicine, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Disc Medicine, Inc..

Disc Medicine, Inc. Ownership

HolderNameConfidenceEvidence
IRON-OWNER-FMR-LLC FMR LLC 90% 13F overlay lists FMR LLC as top holder; 207 tracked holders.

Disc Medicine, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
KURA Kura Oncology, Inc. 100.00 2
REPL Replimune Group, Inc. 100.00 2
ABBV AbbVie Inc. 100.00 1 ['customer', 'supplier']
SVRA Savara Inc. 100.00 2
SGHT Sight Sciences, Inc. 100.00 2
RCUS Arcus Biosciences, Inc. 100.00 2
ALT Altimmune, Inc. 100.00 2
CRS Carpenter Technology Corporation 100.00 1 ['customer']
ENGN enGene Therapeutics Inc. 100.00 2
SI Shoulder Innovations, Inc. 100.00 1 ['customer']
MDGL Madrigal Pharmaceuticals, Inc. 100.00 2
PHGE BiomX Inc. 100.00 2
MRK Merck & Co., Inc. 100.00 2
SNYNF Sanofi 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
KPTI Karyopharm Therapeutics Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
CMPS COMPASS Pathways plc 100.00 2
MAZE Maze Therapeutics, Inc. 100.00 2
Browse supply chain intel →

See the full supply chain map, all relationships, and real-time alerts for Disc Medicine, Inc..

Unlock full IRON data — View plans →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map
🔐
IRON
Unlock IRON Supply Chain Data
Verified relationships include:
ABBVAbbVie Inc.Supplier92%
ABBVAbbVie Inc.Supplier92%
HTGCHercules Capital, Inc.Customer72%
HTGCHercules Capital, Inc.Customer72%
+19 more relationships locked
Subscribe — View plans →
Already a subscriber? Sign in →